Fig. 1: Decreased neuronal PKD levels in striatum from HD patients.
From: Down-regulation of neuroprotective protein kinase D in Huntington´s disease
A Representative confocal microscopy images of PKDT staining (red channel) in neurons (NeuN+, green channel, full arrowhead) and astrocytes (GFAP+, purple channel, empty arrowhead) in striatum from HD patients and control individuals. Scale bar: 40 µm (top panels) and 20 µm (bottom panels). The top graph represents the quantification of PKDT intensity staining in striatal neurons of control individuals compared to HD patients (n = 3 individuals per group). The bottom graph shows the quantification of PKDT staining intensity in striatal astrocytes from control individuals compared to HD patients (21 and 58 GFAP-positive striatal astrocytes in control and HD samples, respectively). Nuclei were stained with DAPI. B PKDT immunohistochemistry in cerebral cortex sections from HD patients and control individuals. Each panel is a representative image from different individuals Scale bar: 100 µm. Chromogen detection was quantified and expressed as the percentage of area stained by PKDT from sections (n = 4 individuals per group). C Representative immunoblot of PKDT and quantification of protein levels in homogenates from striatum necropsies from HD patients (n = 6) and control non-affected individuals (n = 6). Levels of β-actin were used as loading control for normalization purposes. D qRT-PCR analysis of PRKD1 mRNA from striatum and cortex of HD patients (n = 6–8) and non-affected individuals (n = 5–9). Data are represented as mean ± SEM. *P < 0.05 or n.s. (not significant) using unpaired Student’s t test.
